Sterling Pharma Solutions acquires API facility in the US

GERMANTOWN, WI, US - Sep 30, 2020 - Global contract development and manufacturing organisation (CDMO), Sterling Pharma Solutions, has announced its acquisition of Alcamis Germantown, Wisconsin facility in the US.

The new facility will further bolster Sterlings US presence and will provide additional capacity for customer API development and manufacturing projects, specifically those with complex and hazardous requirements.

The Germantown facility houses state-of-the-art cGMP development, scale-up and manufacturing facilities and has specialist expertise in handling technologies including plant-scale hydrogenation and cryogenic reactions

The acquisition follows Sterlings sustained growth over the past four years, which has seen the company invest $46million into its service offering, including a recent $1.5million investment into the companys Cary facility in the US.

Commenting on the announcement, Kevin Cook, CEO of Sterling Pharma Solutions, said: Were delighted to announce our acquisition of the Germantown facility in the US. This is the latest step of our strategic growth plans and will ensure we continue to provide a strong transatlantic API presence to support our customers.

The US market continues to be a key growth area for us. In addition to bolstering our API clinical and commercial manufacturing the Germantown facility has extensive expertise in handling high potency APIs, which will be a valuable addition to our organisation. Were excited to welcome the Germantown team into the Sterling family.

Walt Kaczmarek, Chief Executive Officer of Alcami said: We want to thank the Germantown leadership team and employees for their dedication to the business and wish them success in the future.

Alcami has over 40 years of experience providing comprehensive drug product manufacturing and analytical testing services. This transaction continues our strategy to focus investments on our core service offerings.

This announcement follows several expansion projects, including Alcamis buildout of the sterile manufacturing site in Charleston, SC and the TriPharm acquisition completed in January 2020. Alcami is adding substantial sterile manufacturing and laboratory capacity with best-in-class facility and equipment design.

ENDS

Notes to editors

About Sterling

Sterling Pharma Solutions is a global contract development and manufacturing organisation (CDMO) and is one of the largest providers of small molecule API development and manufacturing services to the pharmaceutical industry, specialising in handling challenging chemistries. With over 50 years experience, the team can manage the most complex API and API intermediate challenges from proof-of-concept to commercial manufacture.

In addition to the new Germantown facility Sterling also has its HQ in Dudley, Northumberland, UK, as well as laboratories and scale up facilities in Cary, North Carolina, US.

For more information visit www.sterlingpharmasolutions.com.